Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 24, 2018, Eagle Pharmaceuticals, Inc., or the Company, and David E. Riggs entered into a separation agreement, or the Agreement. to the Agreement, the Company and Mr. Riggs have mutually agreed to the terms of Mr. Riggs’ separation from the Company, such date of separation referred to as the Separation Date.

to the Agreement, in exchange for Mr.Riggs’ full general release of claims, the Company has agreed: (i)to extend the exercise period of certain Company stock options previously granted and (ii)to pay the COBRA premiums necessary to continue Mr.Riggs’ health insurance coverage (including coverage for covered dependents, if any) until the earliest of (A)six (6)months after the Separation Date, (B)the expiration of Mr.Riggs’ eligibility for the continuation coverage under COBRA, or (C)the date when Mr.Riggs becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment.

Under the terms of the Agreement, Mr.Riggs will be entitled to exercise any vested equity awards, to the extent they were vested and exercisable as of the Separation Date, until November30, 2019, but in no event later than the original expiration date of each such equity award (or the day before the tenth anniversary of the applicable date of grant of an equity award, if earlier).

The foregoing benefits are in full satisfaction, and in lieu of, any severance Mr.Riggs may have been previously eligible for, including under his offer letter, the Eagle Pharmaceuticals,Inc. Officer Severance Benefit Plan, as amended, or otherwise. The Agreement will become effective on the eighth day following Mr.Riggs’ execution thereof, unless revoked by Mr.Riggs prior to such day.

The foregoing summary of the Agreement is not intended to be complete and is qualified in its entirety by reference to the full text of the Agreement, which is filed as Exhibit10.1 to this Current Report on Form8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

ExhibitNo.

Description

10.1

Separation Agreement dated January24, 2018


EAGLE PHARMACEUTICALS, INC. Exhibit
EX-10.1 2 a18-3967_1ex10d1.htm EX-10.1 Exhibit 10.1     January 19,…
To view the full exhibit click here

About Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). It has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). Its near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.

An ad to help with our costs